Skip to main content

Leader in innovation

Our Company

Founded in 2006 and acquired by ZOLL in 2021, Respicardia is a leader in innovative technologies that address the unmet needs of people with Central Sleep Apnea (CSA). CSA results from the brain’s inability to send appropriate signals to the respiratory muscles to stimulate breathing during sleep. CSA is a serious breathing disorder that disrupts the normal breathing pattern and negatively affects quality of life and overall health.1

The remedē System, which received CE mark in 2010 and U.S. Food and Drug Administration (FDA) approval in October 2017, is a breakthrough implantable system that treats CSA by restoring a more normal breathing pattern during sleep.2

  1. Costanzo MR, Khayat R, Ponikowski P, et al. State-of-the-art review: Mechanisms and clinical consequences of untreated central sleep apnea in heart failure. J Am Coll Cardiol 2015;65:72-84.
  2. Costanzo M, et al. Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. The Lancet. 2016; 388: 974–82.